Biomaterials for Neural Tissue Engineering
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 2565
Special Issue Editor
Special Issue Information
Dear Colleagues,
Neural regeneration, especially in the central nervous system, has always been a limiting factor in overcoming sequelae from stroke, traumatic brain injuries, and neurodegeneration caused by diseases such as Alzheimer’s and Parkinson’s. Brain injury sequelae are responsible for emotional, social, and financial impacts on millions of people around the globe. Recent advances in the discovery and development of new biomaterials have allowed the scientific community to explore the possibility of bioengineering neural tissue to repair the damaged brain, similar to what has been done in the past two decades for the peripheral nervous system. Besides the possibility of the regenerative use of bioengineered neural tissues, new biomaterials allow the development of neural-like tissues to study drug delivery to the brain, virus infections, and the cellular as well as molecular mechanisms of neurodegenerative disorders.
This Special Issue aims to highlight recent research on biomaterials in neural tissue engineering. The primary aim of this Special Issue is, but not limited to, to explore the use of biomaterials to fabricate neural tissues to be used as:
- In vitro models to study brain diseases.
- In vitro models for drug screening or drug repositioning.
- Bio patches for brain repair.
Aspects of the characteristics of biomaterials, such as their rigidity, permeability, integration into in vivo tissues, and others, will also be relevant to this Special Issue. Research on the effects of biomaterials on cell proliferation, migration, apoptosis, and fate induction is very relevant for the discussion regarding the use of biomaterials for neural tissue engineering.
We kindly invite the submission of original research and reviews for this Special Issue.
We are looking forward to receiving your contribution.
Dr. Marimelia Porcionatto
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomaterials
- neural tissue
- bioengineering
- 3D model
- CNS diseases
- neurodegeneration
- drug screening
- drug repositioning
- regenerative medicine
